MedTrace Logo

A Phase Ia/Ib Study of HW221043 in Participants With Advanced Solid Tumors

NCT07719920 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2026-07-22

No results posted yet for this study

Summary

This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and preliminary efficacy of HW221043 tablets in participants with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and the dose expansion study (Phase Ib).

Conditions

Interventions

DRUG

HW221043 Tablets

HW221043 Tablets for oral administration at specified doses on scheduled days.

Sponsors & Collaborators

  • Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-30
Primary Completion
2029-06-30
Completion
2029-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07719920 on ClinicalTrials.gov